Work

Assessment of the Right-to-Try Law: The Pros and the Cons

Year: 2018

Type: article

Abstract: On May 30, 2018, the Right-To-Try bill, allowing the use of experimental, non-Food and Drug Administration (FDA)–approved drugs as a last resort for those unable to participate in clinical testing who have also exhausted all other treatment options, was signed into law ([1][1]). At the time this

Source: Journal of Nuclear Medicine

DOI: 10.2967/jnumed.118.216945

Authors: Brandon Brown, Camerin Ortiz, Karine Dubé

Institutions: University of California, Riverside, Syracuse University, University of North Carolina at Chapel Hill

Language: English

Topic: Biomedical Ethics and Regulation

Subfield: Physiology

Field: Medicine

Domain: Health Sciences

SDGs: Peace, justice, and strong institutions, Good health and well-being

Open Access status: bronze

OpenAlex ID: W2886525232